Date published: 2026-8-27

1-800-457-3801

SCBT Portrait Logo
Seach Input

DDX21 CRISPR/Cas9 KO Plasmid (bovine): sc-437356

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: bovine
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • DDX21 CRISPR/Cas9 Knockout (KO) Plasmid (bovine) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DDX21 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    DDX21 CRISPR/Cas9 KO Plasmid (bovine)

    sc-437356
    20 µg
    $397.00

    Overview

    DDX21 encodes a nucleolar DEAD-box RNA helicase that coordinates multiple steps of ribosome biogenesis, including pre-rRNA transcription and processing, and supports RNA polymerase I–dependent nucleolar function. Through its RNA remodeling activity, DDX21 helps integrate rRNA maturation with broader RNA metabolic programs that influence cell-cycle progression, proteostasis, and responses to cellular stress. Perturbation of DDX21 function is associated with altered nucleolar integrity and translational capacity, processes that are frequently studied in contexts such as proliferative signaling, genome stability, and stress-adaptation phenotypes. In bovine systems, DDX21 is relevant for mechanistic investigations of growth and development, host–pathogen interactions that impact ribosome output, and nucleolus-linked regulation of gene expression.

    DDX21 CRISPR/Cas9 KO Plasmid (bovine) is a pool of plasmids designed for targeted disruption of the gene in bovine cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DDX21 protein expression.

    This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of DDX21 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting exon(s) critical for DDX21 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by DDX21 CRISPR/Cas9 KO Plasmid (bovine) and DDX21 CRISPR/Cas9 KO Plasmid (bovine2) target distinct sites within the locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by DDX21 HDR Plasmid (bovine) and DDX21 HDR Plasmid (bovine2) contain a puromycin resistance cassette and an RFP reporter flanked by homology arms to support homology-directed repair at defined target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.